URGN - UroGen: All Eyes On UGN-102

2024-03-18 07:35:24 ET

Summary

• JELMYTO revenues are growing but not by enough to support UroGen's operations.
• Guided financials show ongoing losses with adequate liquidity for its near term UGN-102 development.
• If all goes as hoped UroGen will launch UGN-102 in Q1, 2025.

This is my second UroGen ( URGN ) article following 12/2023's "Urogen: Binary Bet On UGN-102" (" Binary Bet "). In Binary Bet I cautioned about Urogen's gut wrenching volatility; this volatility is likely to continue as it awaits developments on its lead therapy UGN-102 in treatment of low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC)....

For further details see: